Business Context and Reporting Period
Company: InMode Ltd. (INMD)
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: InMode is a global provider of energy-based, minimally invasive, and non-invasive surgical/medical aesthetic solutions. The company utilizes proprietary Radio Frequency (RF) technologies for face and body contouring, medical aesthetics, and women's wellness. Operations are headquartered in Israel, with significant sales in the United States and international markets.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (USD) | 2024 (USD) | Change |
|---|---|---|---|
| Revenues | $370.5 million | $394.8 million | (6.2%) |
| Gross Profit | $291.0 million | $317.1 million | (8.2%) |
| Gross Margin | 79% | 80% | -100 bps |
| Operating Income | $85.4 million | $112.5 million | (24.1%) |
| Net Income | $93.8 million | $181.3 million | (48.3%) |
| Diluted EPS | $1.43 | $2.25 | (36.4%) |
| Operating Cash Flow | $85.3 million | $132.7 million | (35.7%) |
| Cash & Equivalents | $302.5 million | $155.3 million | +94.8% |
| Total Liquidity | $555.3 million | $596.4 million | (6.9%) |
Note: Total Liquidity includes cash, cash equivalents, marketable securities, and short-term bank deposits.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $24.3 million (6%) primarily due to a $55.0 million drop in minimally invasive platform sales and a $12.7 million drop in hands-free platform sales. This was partially offset by a $43.4 million increase in non-invasive platform sales driven by the 2025 launch of ApexRF and Solaria.
- Geographic Shift: U.S. revenue declined 18.9% to $198.7 million due to economic slowdowns and challenging financing markets. Conversely, international revenue increased 14.5% to $171.8 million, driven by growth in Europe and Asia.
- Profitability Compression: Net income dropped significantly (48%) largely due to a one-time tax benefit in 2024 (release of a $60.1 million valuation allowance on U.S. deferred tax assets) which did not recur in 2025. Operating income declined 24% due to lower revenue volume.
- Share Repurchases: The company completed a share repurchase program in Q2 2025, buying back 6.95 million shares for approximately $127.4 million. As of year-end, 24.98 million shares were held as treasury stock.
Guidance, Outlook, and Risks
- Outlook: Management expects continued growth in consumables and extended warranty revenues as the installed base grows. The company plans to expand its direct sales force in the U.S., Canada, and select international markets.
- Geopolitical Risks: The filing highlights significant risks related to the ongoing conflict in Israel (Israel-Hamas war and regional hostilities). While the company reported the impact on operations was immaterial in 2025, continued instability could disrupt manufacturing, supply chains, and employee availability (military reserve call-ups).
- Regulatory Risks: The company relies on FDA 510(k) clearances. Delays or denials for new products or modifications could harm commercial operations. The company is currently involved in patent litigation against BTL Industries Ltd.
- Legal Proceedings: A putative securities class action lawsuit is pending, alleging false statements regarding business and financial outlook. The company intends to vigorously defend the claims.
Investor Verification Checklist
- Geopolitical Exposure: Verify the current status of the ceasefire in Israel and its potential impact on the company's manufacturing subcontractors and logistics.
- Product Mix Sustainability: Assess whether the growth in non-invasive platforms (ApexRF, Solaria) can sustainably offset the decline in the core minimally invasive portfolio.
- Tax Normalization: Confirm that the 2025 tax expense reflects a normalized rate, as the 2024 results were skewed by a large one-time tax benefit.
- Share Count: Monitor the impact of the significant share repurchase program (approx. 10% of outstanding shares) on future earnings per share calculations.
- Legal Contingencies: Track the progress of the pending securities class action and the patent litigation against BTL Industries.